Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Comparator, Randomized, Open-Label, Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L Ornithine Phenylacetate) vs Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy

Trial Profile

A Phase 2a Comparator, Randomized, Open-Label, Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L Ornithine Phenylacetate) vs Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Ornithine phenylacetate (Primary) ; Rifaximin
  • Indications Liver cirrhosis
  • Focus Pharmacodynamics
  • Sponsors Mallinckrodt Inc.
  • Most Recent Events

    • 06 Dec 2018 Planned End Date changed from 30 Aug 2019 to 30 Jul 2019.
    • 06 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 09 Nov 2018 Planned initiation date changed from 15 Nov 2018 to 15 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top